Patient population demographics, baseline characteristics, and
disposition
The study included enough patients to fulfil the aim in the power calculation. The treatment
groups were comparable at baseline. The patient population recruited is within the target
population for Symbicort Turbuhaler.
not assessed
Patients with multiple events in the same category are counted once in each category and multiple events
in a single patient with the same preferred term are counted once for each patient and category
For the primary outcome variable, time to first severe asthma exacerbation, this study
did not demonstrate any difference between Symbicort maintenance and reliever therapy and Seretide at its highest approved dose.